ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) is anticipated to issue its quarterly earnings data on Monday, March 24th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.
ProMIS Neurosciences Stock Down 2.6 %
NASDAQ:PMN opened at $0.65 on Friday. The company has a market capitalization of $21.08 million, a PE ratio of -6.45 and a beta of 0.58. ProMIS Neurosciences has a 52-week low of $0.62 and a 52-week high of $2.61. The stock has a fifty day simple moving average of $0.85 and a 200-day simple moving average of $0.98.
Wall Street Analyst Weigh In
Separately, Guggenheim reiterated a “buy” rating on shares of ProMIS Neurosciences in a research report on Wednesday, February 26th.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Read More
- Five stocks we like better than ProMIS Neurosciences
- Differences Between Momentum Investing and Long Term Investing
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What Are Dividend Champions? How to Invest in the Champions
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
